Navigation Links
Simcere Pharmaceutical Group Announces Resignation of CFO Frank Zhao
Date:1/13/2011

NANJING, China, Jan. 13, 2011 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China, today announced the resignation of chief financial officer Mr. Frank Zhao for personal reasons, effective January 15, 2011. Simcere's Board of Directors has appointed Mr. Yushan Wan, Simcere's corporate controller, as acting chief financial officer as of the effective date.

"Frank has been a valuable member of our management team and we wish him all the best in his future endeavors," said Mr. Jinsheng Ren, chairman and chief executive officer of Simcere. "I would like to thank him for making great enhancements to our financial management and internal control systems in the past four years, as well as building strong relationships with the investment community."

Mr. Yushan Wan joined Simcere in 2000 and has been serving as the Company's corporate controller since 2007. Mr. Wan has a bachelor's degree in biochemistry and a master's degree in accounting from Nanjing University and is a Chinese Certified Public Accountant.

Mr. Ren commented, "Yushan has a decade of experience working in Simcere's financial department and was most recently our corporate controller. I am confident that with his support we will have a smooth transition ahead of the appointment of a new CFO."

About Simcere Pharmaceutical GroupSimcere Pharmaceutical Group (NYSE: SCR, Simcere) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China. In recent years, Simcere has been focusing its strategy on the development of innovative pharmaceuticals and first-to-market generics. The Company has introduced an innovative anti-cancer medication Endu, first-to-market generics such as Bicun and Anxin, and a first-to-market medication Sinofuan. Simcere manufactures and sells drugs in the oncological, cardiovascular, anti-inflammatory and anti-infection therapeutical areas. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence or mortality rates and for which there is a clear demand for more effective pharmacotherapy including cancer and cardiovascular, cerebrovascular, inflammatory and infectious diseases. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com.Investor and Media Contacts: Email: ir@simcere.com In Nanjing:Yehong ZhangPresidentSimcere Pharmaceutical GroupTel: 86-25-8556-6666 ext 8811In the United States:Kate TellierBrunswick GroupTel: 1-212-333-3810In Beijing:Ruirui JiangBrunswick Group Tel: 86-10-5960-8600In Hong Kong:Joseph Lo Chi-LunBrunswick GroupTel: 852-3512-5000    


'/>"/>

SOURCE Simcere Pharmaceutical Group
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study
2. Simcere Pharmaceutical Group Announces Collaboration with OSI Pharmaceuticals
3. Simcere Pharmaceutical Group to Acquire Additional Stake in Jiangsu Yanshen Biological Technology Stock Co., Ltd.
4. Simcere Pharmaceutical Group Announces Jiangsu Yanshens Voluntary Suspension of Production
5. Simcere Pharmaceutical Group Provides Update on Jiangsu Yanshen
6. Simcere Receives SFDA Approval to Manufacture and Sell Zanamivir in China
7. Simcere Pharmaceutical Group to Announce Fourth Quarter and Fiscal Year 2009 Unaudited Financial Results on Tuesday, March 16, 2010
8. Simcere Pharmaceutical Group Successfully Completes Endostar Phase IV Clinical Study
9. Simceres Diosmectite API Passes EU-GMP Inspection
10. Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2010 Results
11. Simcere Pharmaceutical Group Files Annual Report on Form 20-F
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... PUNE, India , April 28, 2016 /PRNewswire/ ... - Pipeline Review, H1 2016" is a report ... pipeline and helps strengthen R&D pipelines by identifying ... best-in-class products. Company Profiles discussed in ... Menarini Industrie Farmaceutiche Riunite Srl, AbbVie Inc., Abiogen ...
(Date:4/27/2016)... , Schweiz, April 27, 2016 /PRNewswire/ ... des Sachs CEO Forums in Zürich gab ... ihres führenden Wirkstoffkandidaten STR001 zur Erhaltung des ... eingesetzt wurde, bekannt. Für die umfassende Phase-II-Doppelblindstudie ... und Frankreich angeworben. STR001 wird während der ...
(Date:4/27/2016)...   , Total Sales Grow ... Clinical sales grow 16% year-over-year  , ... MKEAY) inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy ... ended March 31, 2016 and provided an update on ... First Quarter 2016 Revenue Results by Category  ...
Breaking Medicine Technology:
(Date:4/28/2016)... ... April 28, 2016 , ... Amada Senior Care, premier provider of non-medical in-home ... – its San Antonio West location. Prior to entering the senior care industry, Amada ... opening of Amada San Antonio West will take place on Friday, April 29th. ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... the development of miniature microphones and headsets announced today that the US Patent ... of integrating in-earphones into a structure. This innovative design creates a lightweight and ...
(Date:4/28/2016)... ... , ... Metabolic Nutrition today announced the upcoming launch of its ... Get Fit and Sports Expo in Orlando, Florida. Attended by pro athletes, ... 29-30, was selected as the perfect event to introduce the highly anticipated GlycoLoad. ...
(Date:4/28/2016)... ... April 28, 2016 , ... The Aging in ... has established an ICD-10-CM code for sarcopenia, giving it recognition for separate reporting and ... effective October 1, 2016. , Sarcopenia is defined as a combination of low muscle ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... to those affected by a health insurance co-operative bankruptcy to receive their ... individuals can receive over 1,500 FDA-approved prescription medications from over 180 American ...
Breaking Medicine News(10 mins):